# Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

Source: https://onco.cc/trials/nct01200485/  
OnCo record `nct01200485` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Rasburicase in Leukaemia, run by M.D. Anderson Cancer Center, completed.

## Summary

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2 is a phase 2 interventional study registered as NCT01200485 by M.D. Anderson Cancer Center, with 55 participants recorded, started 2011-04 and reaching its primary completion in 2016-07. Interventions recorded: Rasburicase, Allopurinol. Conditions recorded: Leukemia, Lymphoma.

Linked to the drug Rasburicase because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01200485
- Phase: 2
- Setting: A Randomized Phase 2 Study to Evaluate the Efficacy of Rasburicase in Patients at Risk for TLS During Two Cycles of Chemotherapy
- Sponsor: M.D. Anderson Cancer Center
- Enrolled: 55

## Sources

- ClinicalTrials.gov NCT01200485: https://clinicaltrials.gov/study/NCT01200485

## Connected records

- cancers: [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/)
- drugs: [Rasburicase](https://onco.cc/drugs/rasburicase/)

---
JSON: https://onco.cc/api/v1/entities/nct01200485.json